secwatch / observer
8-K filed May 16, 2024, 7:59 PM ET ticker REVB CIK 0001810560
other material confidence high sentiment neutral materiality 0.15

Revelation Bio shareholders approve director elections, equity plan increase, auditor ratification

REVELATION BIOSCIENCES, INC.

item 5.07item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0000950170-24-061061
form_type
8-K
ticker
REVB
cik
0001810560
company_name
REVELATION BIOSCIENCES, INC.
filed_at
2024-05-16T23:59:59+00:00
discovered_at
2026-05-14T18:03:20.254717+00:00
generated_at
2026-06-01T21:36:04.761006+00:00
sec_items
["5.07", "9.01"]
event_type
other_material
sentiment
neutral
materiality_score
0.25
calibrated_materiality_score
0.15
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0000950170-24-061061
json_url
https://secwatch.observer/filing/0000950170-24-061061.json
markdown_url
https://secwatch.observer/filing/0000950170-24-061061.md
text_url
https://secwatch.observer/filing/0000950170-24-061061.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1810560/000095017024061061/0000950170-24-061061-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1810560/000095017024061061/revb-20240515.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

57aaaf787f3e058f539081e8a6174950fe64e03d

REVELATION BIOSCIENCES, INC. shareholders approved Approval to increase the number of shares reserved under the Company's 2021 Equity Incentive Plan from 21,623 to 163,294.

Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal.

SEC 8-K Item 5.07 confidence 0.95 SEC evidence

71588b43d923376f821b065125c00b60a7dcf7e0

REVELATION BIOSCIENCES, INC. shareholders approved Ratification of Baker Tilly US, LLP as auditor for fiscal year ending December 31, 2024 at the 2024-12-31 meeting.

Stockholders ratified Baker Tilly US, LLP to audit our financial statements for the fiscal year ending December 31, 2024, based on the votes listed below: For Against Abstain 595,879 18,558 258 There were no broker non-votes regarding this proposal.

SEC 8-K Item 5.07 confidence 0.95 SEC evidence

7aa965fd16aed83aa833154c40394a0d1372c04a

REVELATION BIOSCIENCES, INC. shareholders approved Election of two nominees for Class B director: James Rolke and Jess Roper.

Stockholders approved to elect the two nominees for Class B director named herein to serve until the 2027 Annual Meeting or their successors are duly elected and qualified, based on the votes listed below: Director Nominee For Against Abstain James Rolke 122,822 23,715 6,620 Jess Roper 122,543 27,978 2,636 There were 461,538 broker non-votes regarding the election of directors.

SEC 8-K Item 5.07 confidence 0.95 SEC evidence

Comparable filings

DUOT

Duos Tech annual meeting: all five director nominees elected, auditor ratified

DUOS TECHNOLOGIES GROUP, INC. June 2, 2026, 8:30 AM ET other_material Items 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal.

Comparable filing

Proposal No. 4 : To elect Frank D. Recker, Chief Executive Officer of the Company, to serve as a member of the board of directors and to hold office for a one-year term and until his successor is elected and qualified. Votes For Votes With held Frank D. Recker 13,959,958 2,064,009

Filing page SEC filing

MPT

MPT shareholders elect all directors, approve say-on-pay and equity plan with notable opposition

MEDICAL PROPERTIES TRUST INC June 1, 2026, 4:55 PM ET other_material Items 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal.

Comparable filing

Proposal 2: The ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026: For: Against: Abstensions: Broker Non-Votes: 459,883,831 6,189,396 2,613,330 —

Filing page SEC filing

LODE

Comstock holds AGM; all director nominees elected, auditor and equity plan approved

Comstock Inc. June 1, 2026, 4:15 PM ET other_material Items 5.07, 7.01, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal.

Comparable filing

4. Vote on Comstock Inc. 2026 Equity Incentive Plan. The stockholders approved the Comstock Inc. 2026 Equity Incentive Plan as set forth below. Voted For Voted Against Abstain Broker Non-Votes 25,069,375 1,393,479 1,194,028 21,410,649

Filing page SEC filing

LINC

Annual meeting votes pass; strategic plan presentation attached but content not disclosed

LINCOLN EDUCATIONAL SERVICES CORP May 11, 2026, 7:59 PM ET other_material Items 5.07, 7.01, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal.

Comparable filing

Proposal Number 1 : To elect the following 10 individuals named in the Company’s proxy statement as directors of the Company for a one-year term which will expire at the 2027 Annual Meeting of Shareholders or until their successors are duly elected and qualified. Each nominee for director was elected by a vote of the shareholders as follows: Nominee Votes For Votes Withheld Broker Non-Votes John A Bartholdson 23,626,016 239,935 3,137,471 James J. Burke, Jr. 23,575,182 290,769 3,137,471 Anna Escobedo Cabral 23,599,841 266,110 3,137,471 Kevin M. Carney 23,628,321 237,630 3,137,471 Marta Newhart 23,615,050 250,901 3,137,471 Michael A Plater 23,479,505 386,446 3,137,471 Felecia J. Pryor 23,612,578 253,373 3,137,471 Carlton E. Rose 23,629,625 236,326 3,137,471 Scott M. Shaw 23,647,094 218,857 3,137,471 Sylvia J. Young 23,631,057 234,894 3,137,471

Filing page SEC filing

MRNA

Moderna amends bylaws for federal forum exclusivity; stockholders re-elect directors

Moderna, Inc. May 11, 2026, 7:59 PM ET other_material Items 5.03, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal.

Comparable filing

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, with the votes cast as follows:

Filing page SEC filing

PCT

PureCycle shareholders elect all nine directors, ratify auditor, approve say-on-pay at 2026 annual meeting

PureCycle Technologies, Inc. May 11, 2026, 7:59 PM ET other_material Items 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal.

Comparable filing

Proposal 2 – Ratify the appointment of Grant Thornton, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Abstain Broker Non Vote 127,904,943 406,709 196,157 0

Filing page SEC filing

TKR

Timken enters retention agreement with EVP Hansal Patel through June 2028

TIMKEN CO May 8, 2026, 7:59 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal.

Comparable filing

(3) ratified the appointment of Ernst & Young LLP as its independent auditor for the fiscal year ending December 31, 2026; and FOR AGAINST ABSTAIN BROKER NON-VOTES 61,717,389 1,977,231 35,539 0

Filing page SEC filing

CYTK

Cytokinetics director Smith resigns; stockholders approve 300K-share ESPP increase

CYTOKINETICS INC May 17, 2024, 7:59 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal.

Comparable filing

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555

Filing page SEC filing

Source: SEC EDGAR
accession 0000950170-24-061061
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.